Merck KGaA Shares Jump 2.16% on 3.1% EBITDA Surge, Healthcare Growth, Strategic Gains

The share price rose to its highest level so far this month today, with an intraday gain of 2.16%.

Merck KGaA’s recent financial performance has driven renewed investor optimism, bolstered by a 3.1% year-on-year increase in third-quarter EBITDA pre to €1.67 billion, exceeding analyst expectations. The healthcare and life science segments led the charge, with Mavenclad and Erbitux contributing strong sales growth despite regulatory headwinds. A July acquisition of SpringWorks Therapeutics and the divestiture of the Surface Solutions business added €113 million in gains and $175 million from an FDA priority review voucher sale, directly elevating net profits. Legislative changes in South America and strategic portfolio adjustments further underpinned earnings, while the electronics division’s weaker results were offset by core growth areas.

The company’s revised 2025 guidance reflects confidence in its ability to navigate sector-specific challenges. By narrowing the expected range for net sales and EBITDA pre while maintaining midpoints, Merck signaled stability in its growth trajectory. The healthcare segment’s resilience, driven by demand for biopharma production solutions and rare disease treatments, underscores its long-term positioning. Meanwhile, the electronics division’s declining sales highlight ongoing sectoral imbalances, though Merck emphasized cross-sector synergies to mitigate impacts. With earnings per share guidance raised to €8.20–€8.60 and operating cash flow projected at €3.6 billion–€4 billion, the firm’s financial flexibility and disciplined portfolio management reinforce its appeal to investors navigating a dynamic market landscape.